Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SHR-7787 injection combined with adebrelimab as consolidation therapy after chemoradiotherapy for limited-stage small cell lung cancer
CTR20263353Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHR-7787 and adebrelimab in small cell lung cancer (SCLC), sponsored by Hengrui Therapeutics. Started Oct 2026; status: active.
02
Drugs
SHR-7787adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20263353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263353.